China Pharma Holdings (CPHI) Long-Term Deferred Tax (2020 - 2025)
Historic Long-Term Deferred Tax for China Pharma Holdings (CPHI) over the last 10 years, with Q3 2025 value amounting to $22.7 million.
- China Pharma Holdings' Long-Term Deferred Tax changed N/A to $22.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.7 million, marking a year-over-year change of. This contributed to the annual value of $21.7 million for FY2024, which is 78.48% up from last year.
- As of Q3 2025, China Pharma Holdings' Long-Term Deferred Tax stood at $22.7 million.
- China Pharma Holdings' 5-year Long-Term Deferred Tax high stood at $24.0 million for Q4 2021, and its period low was $21.5 million during Q4 2023.
- For the 5-year period, China Pharma Holdings' Long-Term Deferred Tax averaged around $22.3 million, with its median value being $22.0 million (2022).
- In the last 5 years, China Pharma Holdings' Long-Term Deferred Tax tumbled by 1331.78% in 2021 and then skyrocketed by 78.48% in 2024.
- Quarter analysis of 5 years shows China Pharma Holdings' Long-Term Deferred Tax stood at $24.0 million in 2021, then dropped by 8.33% to $22.0 million in 2022, then dropped by 2.07% to $21.5 million in 2023, then rose by 0.78% to $21.7 million in 2024, then increased by 4.61% to $22.7 million in 2025.
- Its Long-Term Deferred Tax stands at $22.7 million for Q3 2025, versus $22.1 million for Q2 2025 and $21.9 million for Q1 2025.